Prasugrel in der Akut- und
Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle
Stand?

S Silber; T M Helms; C Garlichs; H-R Arntz; J Weil; H Ince; T Klingenheben; S Hoffmann; E Boudriot; H Steiger; C Zugck

doi:10.1055/s-0031-1272567

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2011; 136(15): 782-785
DOI: 10.1055/s-0031-1272567

Arzneimittel & Pharmakotherapie | Review article

Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Prasugrel in der Akut- und Nachbehandlung des akuten Koronarsyndroms: Wie ist der aktuelle Stand?

Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?S. Silber¹ , T. M. Helms² , C. Garlichs³ , H-R. Arntz⁴ , J. Weil⁵ , H. Ince⁶ , T. Klingenheben⁷ , S. Hoffmann⁸ , E. Boudriot⁹ , H. Steiger¹⁰ , C. Zugck¹¹

¹ Kardiologische Praxis und Praxisklinik, Akademische Lehrpraxis der Ludwig-Maximilans-Universität München
²Deutsche Stiftung für chronisch Kranke, Fürth
³ Medizinische Klinik II mit Poliklinik, Universitätsklinikum Erlangen
⁴ Campus Benjamin Franklin, Med. Klinik II, Abt. für Kardiologie und Pulmologie Charite – Universitätsmedizin Berlin
⁵ Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
⁶ Klinik und Poliklinik für Innere Medizin – Abt. Kardiologie, Klinikum der Universität Rostock
⁷Praxis für Kardiologie und ambulante Herzkatheter-Kooperation, Bonn
⁸I. Innere Abteilung / Kardiologie, Vivantes Klinikum Am Urban, Berlin
⁹Klinik für Kardiologie, Herzzentrum der Universität Leipzig
¹⁰Kardiologie Darmstadt
¹¹Innere Medizin III, Kardiologie, Angiologie, Pneumologie, Universitätsklinikum Heidelberg

Abstract

Schlüsselwörter

Prasugrel - Clopidogrel - Akutes Koronarsyndrom

Keywords

Prasugrel - Clopidogrel - acute coronary syndrome

Full Text

References

Literatur

1 Abraham N S, Hlatky M A, Antman E M. et al . ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation. 2010; 122 2619-2633
2 Bhatt D L, Cryer B L, Contant C F. et al . Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010; 363 1909-1917
3 Bonello L, Tantry U S, Marcucci R. et al . Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010; 56 919-933
4 Mega J L, Close S L, Wiviott S D. et al . Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360 354-362
5 Mega J L, Close S L, Wiviott S D. et al . Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009; 119 2553-2560
6 Mega J L, Close S L, Wiviott S D. et al . Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010; 376 1312-1319
7 Mehta S R, Tanguay J F, Eikelboom J W. et al . Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010; 376 1233-1243
8 Montalescot G, Sideris G, Cohen R. et al . Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost. 2010; 103 213-223
9 National institute for for health and clinical excellence .prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. http://www.nice.org.uk/nicemedia/pdf/PrasugrelFADToPMForAppealPeriod.pdf. 2009
10 Price M J. Standard versus high-dose clopidogrel according to platelet function testing After PCI: results of the GRAVITAS Trial. Late breaking clinical trials III. Chicago: American Heart Association (AHA); 2010
11 Serebruany V L. Mortality in the TRITON trial: update from the FDA prasugrel action package. Am J Cardiol. 2010; 105 1356-1357
12 Sibbing D, Braun S, Morath T. et al . Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009; 53 849-856
13 Trenk D, Hochholzer W, Fromm M F. et al . Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51 1925-1934
14 Widimsky P, Wijns W, Fajadet J. et al . Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J. 2010; 31 943-957
15 Wijns W, Kolh P, Danchin N. et al . Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010; 31 2501-2555
16 Wiviott S D, Antman E M, Braunwald E. Prasugrel. Circulation. 2010; 122 394-403
17 Wiviott S D, Braunwald E, Angiolillo D J. et al . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008; 118 1626-1636
18 Wiviott S D, Braunwald E, McCabe C H. et al . Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008; 371 1353-1363
19 Wiviott S D, Braunwald E, McCabe C H. et al . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357 2001-2015
20 Wiviott S D, Trenk D, Frelinger A L. et al . Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007; 116 2923-2932

Prof. Dr. med. Sigmund Silber F.A.C.C., F.E.S.C.

Kardiologische Praxis und Praxisklinik
Akademische Lehrpraxis der Ludwig-Maximilans-Universität München

Am Isarkanal 36

81379 München

Email: sigmund@silber.com